WHO Model List
tenofovir disoproxil fumarate
International nonproprietary name (English: tenofovir disoproxil fumarate). Brand names vary by country.
Indications retained by WHO
Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified; Contact with or exposure to human immunodeficiency virus; Chronic hepatitis B.
Listed forms and strengths
- Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)
Forms retained in the model list; presentations available in each country may differ.
General information from the WHO list. It replaces neither the prescription nor the leaflet: dosage and duration are for the doctor or pharmacist to decide.
Source: WHO electronic Essential Medicines List (2025 edition), checked on 14/11/2026. An error or an imprecision? Let us know
